Evidence item

The report gives the 166-patient randomization and non-significant overall- and progression-free-survival comparisons. DATASET_RESULT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 19335

Source: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC · locator {} · excerpt hash sha256:291ba2caada699b193340b4f3c6e1fca9d398c6972e4df8e29ad2ce9d0698cf3

Exact excerpt

At the June 15, 2026 data cutoff, 166 patient were randomized: 83 to nivolumab/ipilimumab alone and 83 to LCT followed by nivolumab/ipilimumab. ... median overall survival was 52.8 months ... compared with 43.2 months ... (HR 1.14; 95% CI, 0.75-1.74; P=.54). Median progression-free survival was 24.3 months versus 31.3 months, respectively (HR 0.79; 95% CI, 0.54-1.15; P=.22).

Linked claims

Claim	Direction	Relevance	Steps	Counted
7e7d05e6	SUPPORT	DIRECT	0	yes

Audits

None.